Re-Vana Therapeutics
Tom Biancardi is a biopharma industry veteran with over 20 years of financial and operational leadership experience. As an advisor he has assisted numerous pre-commercial companies raise Series A capital and establish early operations including Carisma Therapeutics and Interius Biotherapeutics. He was one of the first employees of Ophthotech Corporation where he helped the company grow from a pre-clinical venture backed startup to a publicly traded biotech company with multiple clinical assets. He also worked with Eyetech Pharmaceuticals where he played a crucial role in the successful launch of the first ever pharmacologic treatment for macular degeneration.
Mr. Biancardi holds an M.B.A. from New York University, and Bachelor of Science degrees in both Mechanical Engineering and Economics from Rutgers University.
This person is not in any offices
Re-Vana Therapeutics
Re-Vana Therapeutics is an ocular pharmaceutical and drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma and ocular infections.